RANI · Rani Therapeutics Holdings, Inc. · Documents

Jun 24

Current report 8-K Events of Jun 17

Entered into a material agreement, Other events

May 30

Current report 8-K Events of May 29

Shareholder vote results

May 6

Current report 8-K

Financial results

May 6

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Net loss $7.48M Diluted EPS -$0.29

Apr 17

Proxy statement DEF 14A Meeting May 29, 2024

Proxy statement

Apr 17

Annual report to holders ARS

Annual report to holders

Apr 17

Proxy statement DEFA14A

Proxy statement

Mar 20

Earnings call

Q4 2023 earnings call

Mar 20

Current report 8-K

Financial results

Mar 20

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Net loss $33.97M Diluted EPS -$1.33

Feb 5

Current report 8-K

Regulation FD disclosure, Other events

Dec 19

Current report 8-K Events of Dec 16

Director or officer change, or executive pay

Dec 14

Current report 8-K

Other events

Nov 8

Current report 8-K

Financial results, Director or officer change, or executive pay

Nov 8

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Net loss $9.2M Diluted EPS $0.36 ▲ 9.1%

Nov 1

Current report 8-K

Entered into a material agreement, Financial results, Exit or restructuring costs

Oct 25

Current report 8-K

Other events

Sep 7

Current report 8-K

Other events

Aug 11

Current report 8-K

Financial results

Aug 11

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Net loss $9.3M Diluted EPS $0.37 ▲ 19.4%

Jun 5

Current report 8-K Events of Jun 1

Entered into a material agreement

May 30

Current report 8-K Events of May 25

Shareholder vote results

May 10

Current report 8-K

Current report

May 10

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Net loss $8.37M Diluted EPS $0.33 ▲ 13.8%

Apr 11

Proxy statement DEF 14A Meeting May 25, 2023

Proxy statement

Apr 11

Proxy statement DEFA14A

Proxy statement

Apr 5

Current report 8-K Events of Mar 30

Other events

Mar 22

Earnings call

Q4 2022 earnings call

Mar 22

Current report 8-K

Financial results

Mar 22

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $0 Net loss $30.59M Diluted EPS -$1.28

Jan 9

Current report 8-K Events of Jan 6

Entered into a material agreement

Jan 5

Current report 8-K

Financial results, Regulation FD disclosure

Dec 30

Current report 8-K Events of Dec 29

New debt or off-balance-sheet obligation

Dec 16

Registration statement S-3

Registration statement

Dec 6

Current report 8-K

Regulation FD disclosure, Other events

Nov 10

Current report 8-K

Financial results

Nov 10

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $0 Net loss $7.96M Diluted EPS -$0.33

Oct 24

Current report 8-K

Other events

Aug 25

Current report 8-K Events of Aug 24

Entered into a material agreement

Aug 10

Current report 8-K

Financial results

Aug 10

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $0 Net loss $7.62M Diluted EPS $0.31

Aug 8

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Aug 1

Registration statement S-3

Registration statement

May 26

Current report 8-K Events of May 25

Shareholder vote results

May 11

Current report 8-K

Financial results

May 11

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Net loss $6.22M

Apr 13

Proxy statement DEF 14A Meeting May 25, 2022

Proxy statement

Apr 13

Proxy statement DEFA14A

Proxy statement

Mar 31

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $2.72M ▲ 488.1% Net loss $8.33M

Mar 29

Earnings call

Q4 2021 earnings call